ACRS - Aclaris Therapeutics, Inc.

3.52
0   0%

Share volume: 2,387,967
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$3.52
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.68%
1 Month
15.41%
3 Months
16.94%
6 Months
83.33%
1 Year
121.38%
2 Year
183.87%
Key data
Stock price
$3.52
P/E Ratio 
0.00
DAY RANGE
$3.40 - $3.60
EPS 
-$0.53
52 WEEK RANGE
$1.05 - $4.89
52 WEEK CHANGE
$130.07
MARKET CAP 
326.119 M
YIELD 
N/A
SHARES OUTSTANDING 
120.595 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
2.23
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,060,702
AVERAGE 30 VOLUME 
$2,736,339
Company detail
CEO: Neal S. Walker
Region: US
Website: aclaristx.com
Employees: 100
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.

Recent news